EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY-NC 4.0

Efficacy of Tegoprazan‐Containing Sequential Eradication Treatment Compared to Esomeprazole‐Containing Sequential Eradication of Helicobacter pylori in South Korea, a Region With High Antimicrobial Resistance: A Prospective, Randomized, Single Tertiary Center Study

Jung Won Lee, Nayoung Kim iD, Jongchan Lee, So Young Jo, Dong Ho Lee

Helicobacter · 2024-09 · 29 (5)

DOI: 10.1111/hel.13143 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Helicobacter, online erschienen am 22.10.2024. Verfasst von Jung Won Lee und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, South Korea. Hauptthemen laut MEDLINE: Helicobacter Infections, Esomeprazole, Helicobacter pylori, Anti-Bacterial Agents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the National Research Foundation of Korea (NRF), the Korean government (MSIT), Ministry of Science and ICT, South Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Treatment with potassium‐competitive acid blockers has shown acceptable efficacy in Helicobacter pylori eradication. In regions like Korea, where the clarithromycin resistance rate is high, alternative combinations like non‐bismuth quadruple therapies have shown favorable results. This study compared the outcomes of sequential eradication therapy with new potassium‐competitive acid blocker tegoprazan and conventional esomeprazole‐containing sequential therapy. Materials and Methods Patients with Helicobacter pylori ( H. pylori ) infection were consecutively recruited. Patients were allocated to either an esomeprazole‐containing sequential or a tegoprazan‐containing sequential therapy group. Sequential therapy comprised esomeprazole (40 mg) or tegoprazan (50 mg) plus amoxicillin (1000 mg) twice daily for the initial 5 days, followed by esomeprazole (40 mg) or tegoprazan (50 mg) with clarithromycin (500 mg) and metronidazole (500 mg) twice daily for the remaining 5 days. Eradication rate, compliance, and adverse events were recorded.

Results

A total of 406 patients with H. pylori infection were enrolled in the trial and analyzed per protocol. Eradication rate by intention‐to‐treat and per‐protocol was 83.8% (95% confidence interval [CI]: 78.7–88.9) for esomeprazole‐containing sequential therapy, and 87.1% (95% CI: 82.5–91.8) for tegoprazan‐containing sequential therapy, with no statistical significance ( p = 0.399). Additionally, there was no statistically significant difference in treatment compliance between the two groups. Nausea was more prevalent (23.3%, 27/202) with sequential tegoprazans than with esomeprazole‐containing sequential therapy (14.2%, 29/204; p = 0.022).

Conclusion

Tegoprazan‐containing 10‐day sequential eradication treatment demonstrated similar eradication efficacy compared to esomeprazole‐containing treatment, even in regions with high antimicrobial resistance, such as Korea. Trial Registration ClinicalTrials.gov : NCT06382493

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Helicobacter InfectionsEsomeprazoleHelicobacter pyloriAnti-Bacterial AgentsDrug Therapy, CombinationHumansRepublic of KoreaMaleFemaleMiddle AgedProspective StudiesAgedTreatment OutcomeAdultDrug Resistance, BacterialTertiary Care CentersMetronidazoleProton Pump InhibitorsAmoxicillinClarithromycinPyrrolesSulfonamides

Stichwörter der Autor:innen

Helicobacter pylorieradicationesomeprazolesequential therapytegoprazan

Substanzen

EsomeprazoleAnti-Bacterial Agents1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamineMetronidazoleProton Pump InhibitorsAmoxicillinClarithromycinPyrrolesSulfonamides

Autor:innen und Institutionen

  • Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, South Korea.
  • Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
  • Research Center for Sex- and Gender-Specific Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
  • Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, South Korea.

ORCID-Profile: Nayoung Kim

Förderung

  • the National Research Foundation of Korea (NRF)
  • the Korean government (MSIT)
  • Ministry of Science and ICT, South Korea

Zitieren

APA

Lee, J. W., Kim, N., Lee, J., Jo, S. Y., & Lee, D. H. (2024). Efficacy of Tegoprazan‐Containing Sequential Eradication Treatment Compared to Esomeprazole‐Containing Sequential Eradication of Helicobacter pylori in South Korea, a Region With High Antimicrobial Resistance: A Prospective, Randomized, Single Tertiary Center Study. Helicobacter, 29(5). https://doi.org/10.1111/hel.13143

Vancouver

Lee JW, Kim N, Lee J, Jo SY, Lee DH. Efficacy of Tegoprazan‐Containing Sequential Eradication Treatment Compared to Esomeprazole‐Containing Sequential Eradication of Helicobacter pylori in South Korea, a Region With High Antimicrobial Resistance: A Prospective, Randomized, Single Tertiary Center Study. Helicobacter. 2024;29(5). doi:10.1111/hel.13143

BibTeX
@article{Lee2024,
  author = {Lee, Jung Won and Kim, Nayoung and Lee, Jongchan and Jo, So Young and Lee, Dong Ho},
  title = {Efficacy of Tegoprazan‐Containing Sequential Eradication Treatment Compared to Esomeprazole‐Containing Sequential Eradication of Helicobacter pylori in South Korea, a Region With High Antimicrobial Resistance: A Prospective, Randomized, Single Tertiary Center Study},
  journal = {Helicobacter},
  year = {2024},
  volume = {29},
  number = {5},
  doi = {10.1111/hel.13143}
}
Kostenlos starten →